Patents by Inventor Philip Robson

Philip Robson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210059959
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: April 10, 2020
    Publication date: March 4, 2021
    Applicant: GW Pharma Limited
    Inventors: Philip ROBSON, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20200206184
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
    Type: Application
    Filed: September 6, 2019
    Publication date: July 2, 2020
    Applicant: GW Pharma Limited
    Inventors: PHILIP ROBSON, Geoffrey Guy
  • Patent number: 10653641
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20180344660
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 6, 2018
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20160361290
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
    Type: Application
    Filed: March 14, 2016
    Publication date: December 15, 2016
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy
  • Patent number: 9017737
    Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: April 28, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
  • Patent number: 8771760
    Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: July 8, 2014
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Philip Robson
  • Publication number: 20110230549
    Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Application
    Filed: April 26, 2011
    Publication date: September 22, 2011
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Philip Robson
  • Patent number: 7968594
    Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: June 28, 2011
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Philip Robson
  • Publication number: 20110038958
    Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.
    Type: Application
    Filed: December 17, 2008
    Publication date: February 17, 2011
    Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
  • Publication number: 20100286098
    Abstract: The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 11, 2010
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Roger Pertwee, Joanna Jamontt
  • Publication number: 20100035978
    Abstract: The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10.
    Type: Application
    Filed: October 31, 2006
    Publication date: February 11, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Philip Robson
  • Publication number: 20090197941
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Application
    Filed: October 11, 2006
    Publication date: August 6, 2009
    Inventors: Geoffrey Guy, Philip Robson
  • Publication number: 20080139667
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
    Type: Application
    Filed: June 7, 2005
    Publication date: June 12, 2008
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy
  • Publication number: 20060247304
    Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Application
    Filed: April 27, 2005
    Publication date: November 2, 2006
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Philip Robson